SB9200(Inarigivir soproxil) Datasheet | DC10729

SB9200(Inarigivir soproxil) — Datasheet

CAT. NO. DC10729

Parameter	Value
Chemical Name	SB9200(Inarigivir soproxil)
CAS No.	942123-43-5
Formula	C25H34N7O13PS
M.Wt	703.62
SMILES	CO[C@@H]1[C@H](OP(=O)(OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2O)SCOC(=O)OC(C)C)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O
Purity	>98%
Storage	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Chemical identity references

Biological Activity

Inarigivir soproxil is an agonist of innate immunity and shows potent antiviral activity against resistant hepatitis C virus (HCV) variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.

In Vitro

Inarigivir soproxil (SB 9200) is an oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus and influenza and has demonstrated activity against hepatitis B virus (HBV). Inarigivir soproxil is shown to inhibit HCV replication and the range of inhibition is comparable between genotypes 1a and 1b. Inarigivir soproxil demonstrates pan-genotypic antiviral activity against HCV. Inarigivir soproxil is active against DAA-resistant HCV variants[1].

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.